Korean Market
PERI
ST PHARM
★★★

ST Pharm Reports Record 2025 Revenue of KRW 331.7B and Operating Profit of KRW 54.9B, Up 21% and 98% YoY – New Oligo Plant Ramp-Up and mRNA CDMO Expansion Drive Growth, Financial Structure Strengthens

 
EXCH
ST PHARM
★★★

Q1 2026 Operating Profit Surges 1,025% YoY, Sales Up 27.7%

 
EXCH
ST PHARM
★

2026 Q1 Earnings Review NDR Hosted by Sangsangin Securities

 
PERI
ST PHARM
★★★

ST Pharm Reports Strong Q1 2026 Results with Record Order Backlog

 
EXCH
ST PHARM
★

IR Attendance at Macquarie Asia Conference 2026 (May 18-20, 2026)

 
OWNR
ST PHARM
★

Insider/Major Shareholder Ownership Report Filed (No Changes)

 
OWNR
ST PHARM
★

Report on Ownership by Executives/Major Shareholders (No Change)

 
OWNR
ST PHARM
★

Lim Jin-seok and Yoon Jeong-yeol borrow from Korea Securities Finance to acquire shares, then fully repay